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INTRODUCTION 
On August 21, 1996, President Clinton signed the Health Insurance 
Portability and Accountability Act of 1996 (HIPAA) into law.1  Over the past 
two decades, the federal Department of Health and Human Services (HHS) 
has published several sets of rules2 implementing the Administrative 
Simplification provisions within HIPAA3 as well as the Health Information 
 
* Lehman Professor of Law and Director, Health Law Program, William S. Boyd School of 
Law, University of Nevada, Las Vegas.  I thank Daniel Hamilton, Dean, William S. Boyd 
School of Law, for his generous financial support of this research project and Emma Babler, 
Research Librarian, Wiener-Rogers Law Library, for locating many of the sources referenced 
in this Article.  Finally, I thank the organizers, participants, and attendees of the Seton Hall 
Law Review Symposium (“The New EU Data Protection Regulation: Transnational 
Enforcement and Its Effects on US Businesses”) for their comments, questions, and ideas 
regarding this Article. 
 1  Health Insurance Portability and Accountability Act of 1996 (HIPAA), Pub. L. No. 
104-191, 110 Stat. 1936 (1996). 
 2  See infra notes 20–35 (referencing several sets of proposed, interim final, and final 
rules). 
 3  HIPAA §§ 261–64 [hereinafter Administrative Simplification Provisions]. 
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Technology for Economic and Clinical (HITECH) Act within the American 
Recovery and Reinvestment Act (ARRA), signed into law by President 
Obama on February 17, 2009.4  These rules include a final rule governing 
the use and disclosure of protected health information by covered entities 
and their business associates (Privacy Rule).5 
On January 25, 2012, the European Commission proposed to protect 
individuals with regard to the processing of personal data and the free 
movement of such data.6  The European Union’s (EU’s) final General Data 
Protection Regulation (GDPR) was published in the Official Journal of the 
European Union on May 4, 2016,7 and will apply beginning May 25, 2018.8 
This Article compares and contrasts three illustrative concepts and 
rights in the Privacy Rule and/or the GDPR, including the concepts of 
authorization and consent, the rights of amendment and rectification, and the 
right to erasure.  Identified similarities reflect the core values of HHS and 
the EU with respect to maintaining the confidentiality and privacy of 
personal data and protected health information, respectively.  Identified 
differences reflect the Privacy Rule’s original, narrow focus on health 
industry participants and individually identifiable health information 
compared to the GDPR’s broad focus on data controllers and personal data.  
Other differences reflect, perhaps, the U.S. health care industry’s significant 
experience with heavy regulation, the health care industry’s willingness to 
accept additional regulation in furtherance of the course of business, and 
specific concerns about the ways in which employers, insurers, and other 
institutions have used individuals’ health information to their detriment. 
This Article proceeds as follows: Part I summarizes the history of the 
Privacy Rule, including the many proposed rules, interim final rules, final 
rules, guidance documents, and resolution agreements published by HHS.9  
Part II reviews the Privacy Rule’s theory of and approach to health 
information confidentiality, including the Privacy Rule’s three rules of 
 
 4  See American Recovery and Reinvestment Act of 2009, Pub. L. No. 111-5, § 13001–
24, 123 Stat. 115 (2009) (containing the Health Information Technology for Economic and 
Clinical Health (HITECH) Act). 
 5  Privacy of Individually Identifiable Health Information, 45 C.F.R. §§ 164.500–
164.534 (2016). 
 6  Commission of the European Communities, Proposal for a Regulation of the European 
Parliament and of the Council on the Protection of Individuals with Regard to the Processing 
of Personal Data and on the Free Movement of Such Data (General Data Protection 
Regulation), COM (2012) 11 final (Jan. 2012). 
 7  Council Regulation (EU) 2016/679 of the European Parliament and of the Council of 
27 April 2016 on the Protection of Natural Persons with Regard to the Processing of Personal 
Data and on the Free Movement of Such Data, and repealing Directive 95/46/EC (General 
Data Protection Regulation), 2016 O.J. (L 119) 1 [hereinafter EU GDPR]. 
 8  Id. art. 99, ¶ 2 (“It shall apply from 25 May 2018.”).  
 9  See infra Part I. 
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individual permission, one of which must be satisfied before a covered entity 
or business associate internally uses or externally discloses an individual’s 
protected health information.10  Part III compares and contrasts the concepts 
of authorization and consent under the Privacy Rule and the GDPR, 
respectively.11  Part IV focuses on the rights of amendment and rectification 
in the Privacy Rule and GDPR, respectively.12  Part V examines the GDPR’s 
right to erasure, also known as the right to be forgotten.13  This Article 
concludes by assessing the similarities and differences between these two 
regulations in these three contexts and explaining the differences with 
reference to principles of health law that may not broadly apply to non-health 
industries. 
I. HISTORY OF THE HIPAA PRIVACY RULE 
As signed into law by President Clinton on August 21, 1996, HIPAA 
had several purposes, including improving portability and continuity of 
health insurance coverage in the individual and group markets, combating 
health care fraud and abuse, promoting the use of medical savings accounts, 
improving access to long-term care services and insurance coverage, and 
simplifying the administration of health insurance.14  The Administrative 
Simplification Provisions, codified at Subtitle F of Title II of HIPAA,15 
directed HHS to issue regulations protecting the privacy16 of individually 
 
 10  See infra Part II. 
 11  See infra Part III. 
 12  See infra Part IV. 
 13  See infra Part V. 
 14  See Health Insurance Portability and Accountability Act of 1996 (HIPAA), Pub. L. 
No. 104-191, 110 Stat. 1936, at Preface (1996) (“An Act [t]o amend the Internal Revenue 
Code of 1986 to improve portability and continuity of health insurance coverage in the group 
and individual markets, to combat waste, fraud, and abuse in health insurance and health care 
delivery, to promote the use of medical savings accounts, to improve access to long-term care 
services and coverage, to simplify the administration of health insurance, and for other 
purposes.”).  The Author has reviewed the history of and the regulatory approach taken in the 
Privacy Rule in a number of prior scholarly articles.  See, e.g., Stacey A. Tovino, Hospital 
Chaplaincy under the HIPAA Privacy Rule: Health Care or “Just Visiting the Sick?”, 2 IND. 
HEALTH L. REV. 51 (2005); Stacey A. Tovino, Medical Privacy, in GOVERNING AMERICA: 
MAJOR DECISIONS OF FEDERAL, STATE, AND LOCAL GOVERNMENTS FROM 1789 TO PRESENT 
(Paul Quirk & William Cunion eds., 2011); Stacey A. Tovino, HIPAA Privacy for Physicians, 
17 PATHOLOGY CASE REV. 160 (2012); Stacey A. Tovino, Gone Too Far: Federal Regulation 
of Health Care Attorneys, 91 OR. L. REV. 813 (2013); Stacey A. Tovino, Silence Is Golden . . . 
Except in Health Care Philanthropy, 48 U. RICH. L. REV. 1157 (2014); Stacey A. Tovino, 
Complying with the HIPAA Privacy Rule: Problems and Perspectives, 1 LOY. U. CHI. J. REG. 
COMPLIANCE (2016); Stacey A. Tovino, Teaching the HIPAA Privacy Rule, 61 ST. LOUIS U. 
L.J. (forthcoming 2017).  With technical and conforming changes, much of Parts I and II of 
this Article are reprinted from these prior scholarly articles with the Author’s permission. 
 15  See Health Insurance Portability and Accountability Act of 1996 (HIPAA), Pub. L. 
No. 104-191, §§ 261–64, 110 Stat. 1936 (1996). 
 16  Elsewhere, the Author defined and distinguished the concepts of privacy and 
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identifiable health information if Congress failed to enact comprehensive 
privacy legislation within three years of HIPAA’s enactment.17  When 
Congress failed to enact privacy legislation by its deadline, HHS incurred 
the duty to adopt privacy regulations.18  The original HIPAA statute clarified, 
however, that any privacy regulations adopted by HHS must be made 
applicable only to three classes of individuals and institutions: (1) health 
plans; (2) health care clearinghouses; and (3) health care providers who 
transmit health information in electronic form in connection with certain 
standard transactions (collectively, covered entities).19 
HHS responded.  On November 3, 1999,20 and December 28, 2000,21 
HHS issued a proposed and final privacy rule (“Privacy Rule”) regulating 
covered entities’ uses and disclosures of protected health information (PHI).  
On March 27, 2002,22 and August 14, 2002,23 HHS issued proposed and final 
 
confidentiality for purposes of discussions addressing the legal responsibilities of health 
industry participants.  See, e.g., Stacey A. Tovino, Functional Magnetic Resonance 
Information: A Case for Neuro Exceptionalism?, 34 FLA. ST. U. L. REV. 415, Parts III(J), IV 
& V (2007).  This Article uses the same definitions and distinctions.  Privacy refers to an 
individual’s interest in avoiding the unwanted collection by a third party of health or other 
information about the individual.  Id.  Confidentiality, on the other hand, refers to the 
obligation of a health industry participant to prevent the unauthorized or otherwise 
inappropriate use or disclosure of voluntarily given and appropriately gathered health and 
other information relating to an individual.  Id.  Although the Privacy Rule actually is a health 
information confidentiality rule—because it sets limits on how health care providers and other 
covered entities can use and disclose appropriately gathered PHI—the Author uses the phrase 
“Privacy Rule” and the word “privacy” in this Article because these are the phrases and words 
selected by HHS and used by the public for the rule and the concepts addressed therein.  See, 
e.g., Health Information Privacy, U.S. DEP’T HEALTH & HUM. SERVS., https://www.hhs.gov 
/hipaa/ (last visited Feb. 13, 2017). 
 17  HIPAA § 264 (“If legislation governing standards with respect to the privacy of 
individually identifiable health information . . . is not enacted by the date that is 36 months 
after the date of the enactment of this Act, the Secretary of Health and Human Services shall 
promulgate final regulations containing such standards . . .”).  
 18  See id. 
 19  Id. § 262(a) (“Any standard adopted under this part shall apply, in whole or in part, to 
the following persons: ‘(1) A health plan. (2) A health care clearinghouse. (3) A health care 
provider who transmits any health information in electronic form in connection with a 
transaction referred to in section 1173(a)(1).’”).  See Standards for Privacy of Individually 
Identifiable Health Information, 64 Fed. Reg. at 59,918.  See generally Standards for Privacy 
of Individually Identifiable Health Information, 64 Fed. Reg. 59,918 & 59,924 (proposed 
Nov. 3, 1999) (to be codified at 45 C.F.R. pts. 160–64) (explaining that HHS did not directly 
regulate any entity that was not a covered entity because it did not have the statutory authority 
to do so).   
 20  Id. 
 21  Standards for Privacy of Individually Identifiable Health Information, 65 Fed. Reg. 
82,462 (Dec. 28, 2000). 
 22  Standards for Privacy of Individually Identifiable Health Information, 67 Fed. Reg. 
14,776 (proposed Mar. 27, 2002) (to be codified at 45 C.F.R. pts. 160–64). 
 23  Standards for Privacy of Individually Identifiable Health Information, 67 Fed. Reg. 
53,182 (Aug. 14, 2002). 
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modifications to the Privacy Rule.  With the exception of technical 
corrections and conforming amendments,24 these rules as reconciled 
remained largely unchanged between 2002 and 2009. 
The nature and scope of the legal duties of confidentiality that applied 
to covered entities and their business associates (BAs)25 changed 
significantly eight years ago.  On February 17, 2009, President Obama 
signed ARRA into law.26  Division A, Title XIII of ARRA, better known as 
HITECH, contained certain provisions requiring HHS to modify some of the 
information use and disclosure requirements and definitions set forth in the 
Privacy Rule, adopt new breach notification rules, and amend the civil 
penalty amounts that may be imposed on covered entities and BAs who 
violate the Privacy Rule.27 
Since ARRA’s enactment, HHS has issued several sets of proposed 
rules, interim final rules, final rules, and technical corrections both 
implementing HITECH’s required changes to the Privacy Rule as well as 
responding to other national health information confidentiality concerns.  On 
August 24, 2009, for example, HHS released an interim final rule 
implementing HITECH’s new breach notification requirements.28  On 
 
 24  See, e.g., Standards for Privacy of Individually Identifiable Health Information, 
Correction of Effective and Compliance Dates, 66 Fed. Reg. 12,434 (Feb. 26, 2001); 
Technical Corrections to the Standards for Privacy of Individually Identifiable Health 
Information Published December 28, 2000, 65 Fed. Reg. 82,944 (Dec. 29, 2000). 
 25  Business associates (BAs) are defined to include individual and institutions who: (1) 
on behalf of a covered entity, but other than in the capacity of a member of the workforce of 
a covered entity, create, receive, maintain, or transmit PHI for a function or activity regulated 
by the HIPAA Privacy Rule; and (2) provide, other than in the capacity of a member of the 
workforce of such covered entity, legal, actuarial, accounting, consulting, data aggregation, 
management, administrative, accreditation, or financial services to or for the covered entity.  
See Modifications to the HIPAA Privacy, Security, Enforcement, and Breach Notification 
Rules Under the Health Information Technology for Economic and Clinical Health Act and 
the Genetic Information Nondiscrimination Act; Other Modifications to the HIPAA Rules, 78 
Fed. Reg. 5,566, 5,688 (Jan. 25, 2013) (adopting 45 C.F.R. § 160.103 and providing a new 
definition of business associate). 
 26  See American Recovery and Reinvestment Act of 2009, Pub. L. No. 111-5, § 13001–
24, 123 Stat. 115 (2009). 
 27  Id.  Elsewhere, the Author critiqued HITECH’s imposition of confidentiality 
requirements directly on BAs and proposed statutory and regulatory changes to HITECH and 
the HIPAA Privacy Rule, respectively, that would except a class of BAs, including outside 
counsel, from the confidentiality obligations imposed on other BAs.  See Stacey A. Tovino, 
Gone Too Far: Federal Regulation of Health Care Attorneys, 91 OR. L. REV. 813, 813–67 
(2013).  Elsewhere, the Author also critiqued HITECH’s loosening of the regulatory provision 
that governs covered entities’ uses and disclosures of protected health information for 
fundraising purposes.  See Stacey A. Tovino, Silence Is Golden . . . Except in Health Care 
Philanthropy, 48 U. RICH. L. REV. 1157 (2014).  This Article builds on the Author’s earlier 
work in a new dimension; that is, by comparing illustrative provisions in the HIPAA Privacy 
Rule to the EU GDPR. 
 28  Breach Notification for Unsecured Protected Health Information, 74 Fed. Reg. 42,740 
(Aug. 24, 2009).  
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October 30, 2009, HHS released an interim final rule implementing 
HITECH’s strengthened enforcement provisions, including strengthened 
civil monetary penalties that the federal Office for Civil Rights (OCR) may, 
for the first time since the enactment of the HIPAA statute, impose directly 
on BAs who fail to maintain the confidentiality of PHI.29  On May 31, 2011, 
HHS released a proposed rule that would modify the HIPAA Privacy Rule’s 
accounting of disclosures requirement.30  On January 25, 2013, HHS 
released a final rule modifying the HIPAA Privacy, Security, Breach 
Notification, and Enforcement Rules in accordance with HITECH (“Final 
Regulations”).31  On June 7, 2013, HHS released technical corrections to the 
Final Regulations.32  On September 16, 2013, HHS released a Model Notice 
of Privacy Practices designed to assist covered entities in complying with the 
Final Regulations.33  On February 6, 2014, HHS released a final rule 
modifying the Privacy Rule to provide individuals with a right to receive 
their laboratory test results directly from their testing laboratories.34  Most 
recently, on January 6, 2016, HHS released a final rule that modifies the 
Privacy Rule and permits certain covered entities to disclose PHI to the 
National Instant Criminal Background Check System.35 
As of this writing, HHS has also released fifty-one resolution 
agreements and notices of final determination.36  In these agreements and 
notices, covered entities resolve to comply with the Privacy Rule, report to 
HHS regarding its compliance with the Privacy Rule, pay a resolution 
amount, and/or pay a civil money penalty.37  For example, on February 1, 
 
 29  HIPAA Administrative Simplification: Enforcement, 74 Fed. Reg. 56,123 (Oct. 30, 
2009). 
 30  HIPAA Privacy Rule Accounting of Disclosures Under the Health Information 
Technology for Economic and Clinical Health Act, 76 Fed. Reg. 31,426 (proposed May 31, 
2011) (to be codified at 45 C.F.R. pt. 164). 
 31  See Modifications to the HIPAA Privacy, Security, Enforcement, and Breach 
Notification Rules Under the Health Information Technology for Economic and Clinical 
Health Act and the Genetic Information Nondiscrimination Act; Other Modifications to the 
HIPAA Rules, 78 Fed. Reg. 5566, 5566 (Jan. 25, 2013). 
 32  See Technical Corrections to the HIPAA Privacy, Security, and Enforcement Rules, 
78 Fed. Reg. 34,264, 34,266 (June 7, 2013).  
 33  Model Notices of Privacy Practices, U.S. DEP’T HEALTH & HUMAN SERVS., 
http://www.hhs.gov/hipaa/for-professionals/privacy/guidance/model-notices-privacy-
practices/ (last visited Apr. 17, 2017).  
 34  CLIA Program and HIPAA Privacy Rule; Patients’ Access to Test Reports, 79 Fed. 
Reg. 7290 (Feb. 6, 2014). 
 35  Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule and the 
National Instant Criminal Background Check System (NICS), 81 Fed. Reg. 382, 396 (Jan. 6, 
2016).  
 36  See Resolution Agreements, U.S. DEP’T HEALTH & HUMAN SERVS., http://www.hhs 
.gov/hipaa/for-professionals/compliance-enforcement/agreements/index.html (last visited 
Apr. 17, 2017).  
 37  See id. 
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2017, HHS issued a press release announcing a recent notice of final 
determination, which imposed a civil money penalty (CMP) on Children’s 
Medical Center of Dallas (“Children’s”).38  As background, a workforce 
member of Children’s lost an unencrypted, non-password-protected 
BlackBerry device that contained the PHI of approximately 3,800 
individuals at the Dallas/Fort Worth International Airport.39  In addition, an 
unencrypted laptop containing the PHI of 2,462 individuals was stolen from 
Children’s premises.40  Although Children’s had implemented some physical 
safeguards to protect its laptop storage area, Children’s admitted it provided 
access to the area to workforce personnel not authorized to access PHI.41  By 
letter dated January 18, 2017, HHS imposed a $3,217,000.00 CMP on 
Children’s for these two health information confidentiality breaches as well 
as several other Privacy Rule violations.42 
II. THE HIPAA PRIVACY RULE’S THEORY OF AND APPROACH TO HEALTH 
INFORMATION CONFIDENTIALITY 
A brief summary of the Privacy Rule’s theory and approach to health 
information confidentiality is necessary before proceeding to Part III, which 
compares and contrasts the concepts of authorization and consent under the 
Privacy Rule and the GDPR, respectively. 
The Privacy Rule’s goal is to balance the interest of individuals in 
maintaining the confidentiality of their health information with the interests 
of society in obtaining, using, and disclosing health information to carry out 
a variety of public and private activities.43  To this end, the Privacy Rule 
regulates covered entities’ and BAs’ uses of, disclosures of, and requests for 
individually identifiable health information (IIHI)44 to the extent such 
 
 38  Press Release, U.S. Dep’t Health & Hum. Servs., Lack of Timely Action Risks 
Security and Costs Money (Feb. 1, 2017). 
 39  Id. 
 40  Id. 
 41  Id. 
 42  Letter from Jocelyn Samuels, Dir., Off. C.R., Dep’t Health & Hum. Servs., to Mr. 
David Barry, Pres., Sys. Clinical Operations, Children’s Med. Ctr. 1 (Jan. 18, 2017).  
 43  See Standards for Privacy of Individually Identifiable Health Information, 65 Fed. 
Reg. 82,462, 82,464 (Dec. 28, 2000) (“The rule seeks to balance the needs of the individual 
with the needs of the society.”); id. at 82,468 (“The task of society and its government is to 
create a balance in which the individual’s needs and rights are balanced against the needs and 
rights of society as a whole.”); id. at 82,472 (“The need to balance these competing interests—
the necessity of protecting privacy and the public interest in using identifiable health 
information for vital public and private purposes—in a way that is also workable for the varied 
stakeholders causes much of the complexity in the rule.”). 
 44  The Privacy Rule defines “individually identifiable health information” (IIHI) as 
“information that is a subset of health information, including demographic information 
collected from an individual, and: (1) Is created or received by a health care provider, health 
plan, employer, or health care clearinghouse; and (2) Relates to the past, present, or future 
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information does not constitute: (1) an education record protected under the 
Family Educational Rights and Privacy Act of 1974 (FERPA); (2) a student 
treatment record excepted from protection under FERPA; (3) an employment 
record held by a covered entity in its role as an employer; or (4) individually 
identifiable health information regarding a person who has been deceased 
for more than fifty years.45  The Privacy Rule calls the subset of IIHI 
described in the previous sentence “protected health information.”46 
Before using or disclosing PHI, the Privacy Rule requires covered 
entities and BAs to adhere to one of three different rules depending on the 
purpose of the information use or disclosure.47  These rules reflect HHS’s 
desire to appropriately balance the interest of individuals in maintaining the 
confidentiality of their PHI with a wide range of societal interests in 
obtaining, using, or disclosing PHI, some of which may have greater societal 
importance and value than others.48 
The first rule allows covered entities and BAs to use and disclose PHI 
with no prior permission from the individual who is the subject of the PHI—
but only in certain situations.  That is, covered entities may freely use and 
disclose PHI without any form of prior permission in order to carry out their 
 
physical or mental health or condition of an individual; the provision of health care to an 
individual; or the past, present, or future payment for the provision of health care to an 
individual; and (i) That identifies the individual; or (ii) With respect to which there is a 
reasonable basis to believe the information can be used to identify the individual.”  General 
Administrative Requirements, 45 C.F.R. § 160.103 (2016). 
 45  Id. (defining “protected health information”). 
 46  Id. (using the phrase “protected health information”). 
 47  Standard Unique Health Identifier for Health Plans, 45 C.F.R. §§ 164.502–164.514 
(2016) (setting forth the use and disclosure requirements applicable to covered entities and 
business associates). 
 48  See supra text accompanying note 43. 
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own treatment,49 payment,50 and health care operations51 activities,52 as well 
as certain public benefit activities.53 
As an example of this first rule, a covered general practitioner (GP) who 
wishes to consult with a specialist to treat a patient may disclose PHI to the 
specialist, and the Privacy Rule does not require the patient to give the GP 
prior authorization for the disclosure.54  Likewise, a covered hospital that 
treats a patient may send a bill to the patient’s insurer to obtain payment for 
hospital services rendered without the patient’s prior authorization.55  
Similarly, a teaching physician employed by a covered academic medical 
center may involve medical students, interns, residents, and fellows in 
patient care, without prior authorization from the patients who are receiving 
such care, to enable the students and residents to learn to practice medicine.56  
Furthermore, a covered entity that is required by state or other law to disclose 
PHI to another individual or entity may do so without patient authorization.57  
 
 49  The Privacy Rule defines “treatment” as: 
[T]he provision, coordination, or management of health care and related 
services by one or more health care providers, including the coordination or 
management of health care by a health care provider with a third party; 
consultation between health care providers relating to a patient; or the referral 
of a patient for health care from one health care provider to another.  
Privacy of Individually Identifiable Health Information, 45 C.F.R. § 164.501 (2016). 
 50  The Privacy Rule defines “payment” as the activities “undertaken by a health plan to 
obtain premiums or to determine or fulfill its responsibility for coverage and provision of 
benefits under the health plan” as well as the activities of a “health care provider or health 
plan to obtain or provide reimbursement for the provision of health care.”  Id. 
 51  The Privacy Rule defines “health care operations” with respect to a list of activities 
that are related to a covered entity’s covered functions.  See id. (defining health care 
operations).  These activities include, but are not limited to, conducting quality assessment 
and improvement activities, conducting training programs in which medical and other health 
care students learn to practice health care under supervision, and arranging for the provision 
of legal services.  See id. 
 52  See id. § 164.506(c)(1) (permitting a covered entity to use or disclose PHI for its own 
treatment, payment, or health care operations). 
 53  Covered entities may use and disclose PHI for twelve different public policy activities 
without the prior written authorization of the individual who is the subject of the information.  
See id. § 164.512(a)–(l).  These public policy activities include, but are not limited to, uses 
and disclosures required by law, uses and disclosures for public health activities, disclosures 
for law enforcement activities, uses and disclosures for research, and disclosures for workers’ 
compensation activities.  See id. § 164.512(a), (c), (b), (f), (i) & (l). 
 54  See id. § 164.501 (defining “treatment” to include “consultations between health care 
providers relating to a patient”).  
 55  See Privacy of Individually Identifiable Health Information, 45 C.F.R. § 164.501 
(2016) (defining “payment” to include “the activities undertaken by a health care provider . . . 
to obtain . . . reimbursement for the provision of health care”); id. § 164.506(c)(1) (permitting 
a covered entity to disclose PHI for its own payment activities). 
 56  See id. § 164.501(c)(1) (defining “health care operations” to include “conducting 
training programs in which students, trainees, or practitioners in areas of health care learn 
under supervision to practice or improve their skills as health care providers”). 
 57  See id. § 164.512(a)(1) (allowing covered entities to “use or disclose protected health 
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By final illustrative example, a covered entity may disclose a patient’s PHI 
to a law enforcement officer in certain situations, including when the covered 
entity suspects that the death of the patient may have resulted from criminal 
conduct.58  The theory behind these permitted information uses and 
disclosures is that treating patients, allowing health care providers to obtain 
reimbursement for providing health care, training medical students and 
residents, complying with state law, and alerting law enforcement officers to 
the suspicion of criminal activity outweigh an individual’s interest in 
maintaining complete confidentiality of his or her PHI. 
The first rule requires no prior authorization from the individual who is 
the subject of the information before the information use or disclosure may 
occur.59  Under the second rule, a covered entity may use and disclose an 
individual’s PHI for certain activities, but only if the individual is informed 
in advance of the use or disclosure and has the opportunity to agree to, 
prohibit, or restrict the use or disclosure.60  Because the Privacy Rule allows 
the covered entity to orally inform the individual of (and capture an oral 
agreement or oral objection to) a use or disclosure permitted by these 
provisions, this second rule is sometimes referred to as the “oral permission 
rule,” although a more practical written permission also will suffice. 
Under the second rule, a covered entity may conduct five sets of 
information uses and disclosures once the individual who is the subject of 
the information has been notified and has either agreed or not objected to the 
information use or disclosure.61  These five sets of information uses and 
disclosures include: (1) certain uses and disclosures of directory information, 
such as name, location, general condition, and religious affiliation;62 (2) 
certain uses and disclosures that would allow other persons to be involved in 
a patient’s care or payment for care;63 (3) certain uses and disclosures that 
would help notify, or assist in the notification of, family members, personal 
representatives, and other persons responsible for the care of the individual’s 
location, general condition, or death;64 (4) certain uses and disclosures for 
disaster relief purposes;65 and (5) certain disclosures to family members and 
other persons who were involved in the individual’s care or payment for 
 
information to the extent that such use or disclosure is required by law and the use or 
disclosure complies with and is limited to the relevant requirements of such law”). 
 58  See id. § 164.512(f)(4). 
 59  See supra notes 54–58 and accompanying text. 
 60  See 45 C.F.R. § 164.510. 
 61  See Privacy of Individually Identifiable Health Information, 45 C.F.R. § 164.510 
(2016). 
 62  See id. § 164.510(a). 
 63  See id. § 164.510(b)(1)(i). 
 64  See id. § 164.510(b)(1)(ii). 
 65  See id. § 164.510(b)(4). 
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health care prior to the individual’s death of PHI that is relevant to that 
person’s involvement.66 
As an illustration of the second rule, the hospital room number and 
general condition of a patient (e.g., “good,” “fair,” “poor,” “stable”) who has 
given his or her permission or who has not expressed an objection may be 
disclosed to a visitor who requests directory information about that patient.67  
Likewise, a woman in labor who wishes her partner to be present for her 
labor and delivery may orally give her permission for her health care 
providers to involve her partner in her care.68 
The theory behind requiring at least oral permission for these 
information uses and disclosures is that the patient has an interest in 
maintaining the confidentiality of his or her PHI; however, the patient also 
may have an interest in being visited in the hospital, in obtaining assistance 
with the patient’s health care or payment for health care, and being assisted 
during a disaster.  In addition, the patient’s family also may have an interest 
in visiting the patient in the hospital, assisting the patient with his or her 
health care and financial needs, and obtaining assistance during a disaster.  
The required oral permission reflects the individual’s interest in maintaining 
the confidentiality of his or her health information, but the lack of a 
requirement for a formal written authorization reflects HHS’s desire to make 
it easy for the individual to ask for or agree to receive help. 
III. THE CONCEPTS OF AUTHORIZATION AND CONSENT 
The third rule––a default rule––requires covered entities and BAs to 
obtain the prior written authorization from the individual who is the subject 
of the PHI before using or disclosing the individual’s PHI in any situation 
that does not fit under the first or second rule.69  Stated another way, in the 
event that a covered entity or BA would like to use or disclose PHI for a 
purpose (1) that is not treatment, payment, or health care operations; (2) that 
does not fall within one of twelve public benefit exceptions; (3) that is not 
allowed with oral permission or without an objection; and (4) that is not 
otherwise permitted or required by the Privacy Rule, the covered entity must 
obtain the prior written authorization from the individual who is the subject 
of the information.70 
 
 66  See Privacy of Individually Identifiable Health Information, 45 C.F.R. § 164.501(b)(5) 
(2016). 
 67  See id. § 164.510(a)(1), (2). 
 68  See id. § 164.510(b)(1)(i). 
 69  See id. § 164.508(a)(1). 
 70  See id. § 164.508(a)(1).  
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A. Definitions, Conceptualizations, Content, and Format 
The Privacy Rule does not formally define “authorization” in a 
definition regulation; instead, the concept of authorization simply exists as a 
default rule.  The Privacy Rule does, however, specify the form of the 
authorization required by the third rule, including certain elements and 
statements that are designed to place the individual on notice of how the 
individual’s PHI will be used or disclosed.71  These elements and statements 
include: 
(i) [a] description of the information to be used or disclosed that 
identifies the information in a specific and meaningful fashion; (ii) 
[t]he name or other specific identification of the person(s), or class 
of persons, authorized to make the requested use or disclosure; 
(iii) [t]he name or other specific identification of the person(s), or 
class of persons, to whom the covered entity may make the 
requested use or disclosure; (iv) [a] description of each purpose of 
the requested use or disclosure; (v) [a]n expiration date or an 
expiration event that relates to the individual or the purpose of the 
use or disclosure; (vi) [s]ignature of the individual and date.72 
The regulations also require: (i) a statement regarding the individual’s 
right to revoke the authorization in writing together with the exceptions to 
the right to revoke; (ii) a statement regarding the ability or inability of the 
covered entity or BA “to condition treatment, payment, enrollment, or 
eligibility for benefits on the authorization;” and (iii) a statement regarding 
“the potential for information disclosed pursuant to the authorization to be 
subject to redisclosure by the recipient and no longer be protected by [the 
Privacy Rule.]”73  HIPAA-compliant authorization forms also must be 
written in plain language.74 
The high level of prior individual permission required by HIPAA’s 
authorization form reflects the value HHS places on an individual’s interest 
in maintaining the confidentiality of his or her PHI compared to other 
societal interests that are far removed from the core functions of covered 
entities and BAs.  Some of the societal interests include a health care 
provider’s interest in selling the patient’s information to a tabloid magazine 
or a health plan’s interest in disclosing the patient’s information to a 
marketing company to allow the company to market its products and services 
to the individual.75 
 
 71  See id. § 164.508(c)(1), (2). 
 72  Privacy of Individually Identifiable Health Information, 45 C.F.R. § 164.508(c)(1) 
(2016) (listing six core elements). 
 73  Id. § 164.508(c)(2) (listing three required statements). 
 74  Id. § 164.508(c)(3). 
 75  See Standards for Privacy of Individually Identifiable Health Information, 65 Fed. 
Reg. 82,462, 82,514 (Dec. 28, 2000) (“[C]overed entities must obtain the individual’s 
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Unlike the Privacy Rule, which does not specifically define 
“authorization,” the GDPR defines “consent” as any “freely given, specific, 
informed and unambiguous indication of the data subject’s . . . agreement to 
the processing of personal data relating to him or her.”76  Under the GDPR, 
consent is less of a default concept and more of a primary requirement with 
acceptable alternatives.  That is, under the GDPR, the processing of personal 
data shall be lawful only if and to the extent one of the following applies: 
(a) the data subject has given consent . . .; (b) processing is 
necessary for the performance of a contract to which the data 
subject is party or in order to take steps at the request of the data 
subject prior to entering into a contract; (c) processing is necessary 
for compliance with a legal obligation to which the controller is 
subject; (d) processing is necessary in order to protect the vital 
interests of the data subject or of another natural person; (e) 
processing is necessary for the performance of a task carried out 
in the public interest or in the exercise of official authority vested 
in the controller; or (f) processing is necessary for the purposes of 
the legitimate interests pursued by the controller or by a third 
party, except where such interests are overridden by the interests 
or fundamental rights and freedoms of the data subject which 
require protection of personal data, in particular where the data 
subject is a child.77 
With respect to the content of the consent, the GDPR only requires that 
the data subject be made aware of “the fact that and the extent to which 
consent is given.”78  For the subject’s consent to be considered informed, the 
GDPR also requires the data subject to be aware of, at least, “the identity of 
the controller and the purposes of the processing for which the personal data 
are intended.”79 
According to the GDPR, a consent that is created by the data controller 
should be provided to the subject “in an intelligible and easily accessible 
form, using clear and plain language and it should not contain unfair terms.”80  
In terms of format, a consent for the processing of personal data—not data 
concerning health—can be a written statement, as is required by the Privacy 
Rule for the use or disclosure of PHI under the third rule of individual 
permission; but it could also be satisfied by an electronic ticking of a box or 
 
authorization before using or disclosing protected health information for marketing 
purposes.”).  
 76  EU GDPR, supra note 7, art. 4(11). 
 77  Id. art. 6(1) (emphasis added).  
 78  Id. pmbl., ¶ 42. 
 79  Id. 
 80  Id. 
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even an oral statement indicating agreement to personal data processing.81  
In comparison, and as discussed in Part II, oral agreement to the use and 
disclosure of PHI under the Privacy Rule is only permitted in the context of: 
(1) disclosures of directory information; (2) disclosures to persons involved 
in patients’ care and payment for care; (3) disclosures for notification 
purposes; (4) disclosures for disaster relief purposes; and (5) disclosures 
when the individual is deceased.82 
Notwithstanding the GDPR’s loose conceptualization of and format for 
the consent for the processing of personal data, the GDPR expressly prohibits 
the processing of personal data concerning health unless the data subject has 
given “explicit” consent or an exception applies.83  In addition, the GDPR 
does allow Member States to maintain or introduce further limitations on the 
processing of health data,84 much in the same way states in the U.S. are 
permitted to have more stringent laws protecting health information 
confidentiality relative to the Privacy Rule’s federal floor.85 
B. Conditioning 
To ensure that an individual’s prior written authorization for the use or 
disclosure of his or her PHI under the Privacy Rule is freely given, the 
Privacy Rule also contains a general “no conditioning” rule.  That is, the 
Privacy Rule generally prohibits covered entities from conditioning 
treatment, payment, enrollment, or eligibility on an individual’s provision of 
an authorization, although there are three exceptions.86  As discussed above, 
an individual who signs an authorization for the use or disclosure of PHI 
must be notified in the authorization form itself about the “no conditioning” 
rule, the exceptions to the rule, and the consequences of a refusal to sign an 
authorization form when conditioning is permitted.87 
Here, the GDPR is similar although not quite as strong.  In other words, 
the GDPR does have a requirement that consent for the processing of 
personal data be freely given.88  In assessing if consent is freely given, the 
GDPR looks at three factors, including: (1) whether the data subject has 
 
 81  Id. ¶ 32. 
 82  Privacy of Individually Identifiable Health Information, 45 C.F.R. § 164.510 (2016). 
 83  EU GDPR, supra note 7, art. 9, ¶ 2(a).  
 84  Id. art. 9, ¶ 4. 
 85  General Administrative Requirements, 45 C.F.R. § 160.203(b) (2016) (stating that the 
Privacy Rule generally preempts a contrary provision of state law unless the state law is more 
stringent than the Privacy Rule); id. § 160.202 (defining “more stringent”). 
 86  Privacy of Individually Identifiable Health Information, 45 C.F.R. § 164.508(b)(4) 
(2016).  See infra note 94 and accompanying text for exceptions. 
 87  § 164.508(c)(2)(ii)(A), (B). 
 88  EU GDPR, supra note 7, pmbl., ¶ 32; id., art. 4, ¶ 11. 
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genuine, free choice in deciding whether to give consent;89 (2) whether the 
data subject is unable to refuse to consent;90 and (3) whether the performance 
of a contract is conditioned on the data subject’s consent when consent is not 
necessary for the performance of the contract.91  The last factor expresses a 
concern similar to that embodied in the Privacy Rule’s “no conditioning” 
rule, which is the concern that individuals will be asked to cede their rights 
to data privacy and information confidentiality in order to obtain a desired 
or necessary service.  The difference between the Privacy Rule and the 
GDPR is the strength of the concern.  HHS frames the concept as an outright 
prohibition with only three exceptions, whereas the GDPR simply assesses 
conditioning as an element of the voluntariness of consent. 
C. Separation of Presentation 
Another measure of comparison is the regulations’ separation of 
presentation rules.  To ensure that individuals who give their prior written 
authorization know what they are signing and recognize the importance of 
what they are signing, the Privacy Rule generally prohibits an authorization 
from being combined with another document.92  Instead, the Privacy Rule 
requires an authorization to be presented separately to each individuals for 
his or her signature.93  Only three exceptions to this “no combination” rule 
exist, and these exceptions involve: (1) authorizations combined with 
research-related documentation; (2) two or more authorizations for the use 
or disclosure of psychotherapy notes; and (3) two or more authorizations that 
are not conditioned on treatment, payment, enrollment in a health plan, or 
eligibility for benefits.94 
The GDPR expresses similar concerns about the importance of a data 
subject’s understanding his or her consent to data processing.  The difference 
is that the GDPR expressly permits the combination of a consent with 
another “written declaration which also concerns other matters,” but only if 
the “request for consent [is] presented in a manner which is clearly 
distinguishable from the other matters.”95  Under the GDPR, then, the 
consent does not need to be separate, just presented in a manner that is clearly 
distinguishable. 
 
 89  Id. pmbl., ¶ 42. 
 90  Id. 
 91  Id. art. 7, ¶ 4. 
 92  45 C.F.R. § 164.508(b)(3) (2016). 
 93  See id. § 164.508(b)(3). 
 94  Id. § 164.508(b)(3)(i)–(iii). 
 95  EU GDPR, supra note 7, art. 7, ¶ 2. 
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D. Rights of Revocation and Withdrawal 
Under the Privacy Rule, an individual generally has the right to revoke 
an already-given authorization at any time so long as the revocation is in 
writing.96  The Privacy Rule provides two exceptions to this right to revoke, 
addressing situations in which: (1) the covered entity has already acted in 
reliance on the authorization, including by using or disclosing PHI before the 
revocation was received; and (2) an authorization was obtained as a 
condition of obtaining insurance coverage and other law provides the insurer 
with the right to contest a claim under the policy or the policy itself.97  The 
Privacy Rule implements the right to revoke by requiring all authorizations 
to contain a statement adequate to place the individual on notice of the 
individual’s right to revoke the authorization, the exceptions to the right to 
revoke, and a description of how the individual may revoke his or her 
authorization.98 
The GDPR has a similar concept known as withdrawal.  That is, the 
GDPR requires the data subject to be allowed to withdraw his or her consent 
at any time unless personal data has already been processed pursuant to the 
prior consent.99  Like the Privacy Rule, the GDPR also requires subjects to 
be informed of their right to withdraw their consent prior to giving 
consent.100 
Where the GDPR is more stringent than the Privacy Rule is with respect 
to the ease of withdrawal.  The GDPR requires it to be as easy for the data 
subject to withdraw his or her consent as it is for the subject to give 
consent.101  HIPAA covered entities, on the other hand, frequently make it 
more difficult for individuals to revoke their authorizations than to give their 
authorization.  For example, many covered hospitals require revocations to 
be sent to the hospital through regular U.S. mail or presented in person to the 
hospital’s Privacy Officer or other health information manager,102 although 
they make their authorizations readily available for online completion and 
 
 96  45 C.F.R. § 164.508(b)(5). 
 97  Id. § 164.508(b)(5)(i), (ii). 
 98  Id. § 164.508(c)(2)(i)(A), (B). 
 99  EU GDPR, supra note 7, pmbl., ¶ 42 (stating that consent is not freely given if the 
individual is unable to withdraw consent); id. art. 7, ¶ 3 (“The data subject shall have the right 
to withdraw his or her consent at any time.  The withdrawal of consent shall not affect the 
lawfulness of processing based on consent before its withdrawal.  Prior to giving consent, the 
data subject shall be informed thereof.  It shall be as easy to withdraw as to give consent.”). 
 100  Id. art. 7, ¶ 3. 
 101  Id. 
 102  See, e.g., Protected Health Information (PHI) Release Authorization, U. MED. CTR. 1, 
https://www.umcsn.com/Common/Documents/authorization_disclose_health_info.pdf (last 
visited Apr. 17, 2017) (“Revocation must be made in writing and presented or mailed to the 
UMC Health Information Management Department at the following address: 1800 W. 
Charleston Blvd., Las Vegas, Nevada 89102.”) (emphasis in original).  
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submission.103 
E. Marketing 
Another point of comparison is that of marketing.  If a communication 
falls within the Privacy Rule’s definition of marketing,104 the Privacy Rule 
prohibits a covered entity or BA from using or disclosing an individual’s PHI 
for marketing unless the individual signs a specific authorization form noting 
that the purpose of the use or disclosure is marketing and stating whether any 
remuneration associated with the marketing exists,105 unless an exception to 
the marketing authorization requirement applies.106 
The GDPR is similar in terms of its dislike for what it calls “direct 
marketing,” requiring the processing of personal data for direct marketing to 
be “explicitly brought to the attention of the data subject,” requiring it to be 
“presented clearly and separately from any other information,” giving the 
data subject a clear right to object to the processing of his or her personal 
data for direct marketing, and actually setting forth a prohibition against 
marketing following such an objection.107 
 
 
 103  See, e.g., Authorization for Release of Health Information Pursuant to HIPAA, OCA 
Official Form No.: 960, N.Y. ST. DEP’T HEALTH, http://www.nycourts.gov/forms/hipaa 
_fillable.pdf (last visited Apr. 17, 2017) (offering a fillable, electronic HIPAA-compliant 
authorization form).  
 104  Privacy of Individually Identifiable Health Information, 45 C.F.R. § 164.501 (2016) 
(defining marketing as the making of a communication about a product or service that 
encourages recipients of the communication to purchase or use the product or service; 
excluding from the definition of marketing communications made for purposes of: (1) 
Providing refill reminders or otherwise communicating about a drug or biologic that is 
currently being prescribed for the individual, but only if any financial remuneration received 
by the covered entity in exchange for making the communication is reasonably related to the 
covered entity’s cost of making the communication; (2) For the following treatment and health 
care operations purposes, except where the covered entity receives financial remuneration in 
exchange for making the communication: (A) For treatment of an individual by a health care 
provider, including case management or care coordination for the individual, or to direct or 
recommend alternative treatments, therapies, health care providers, or settings of care to the 
individual; (B) To describe a health-related product or service (or payment for such product 
or service) that is provided by, or included in a plan of benefits of, the covered entity making 
the communication, including communications about: the entities participating in a health 
care provider network or health plan network; replacement of, or enhancements to, a health 
plan; and health-related products or services available only to a health plan enrollee that add 
value to, but are not part of, a plan of benefits; or (C) For case management or care 
coordination, contacting of individuals with information about treatment alternatives, and 
related functions to the extent these activities do not fall within the definition of treatment). 
 105  Id. § 164.508(a)(3)(i), (ii).  
 106  Id. § 164.508(a)(3)(i)(A), (B). 
 107  EU GDPR, supra note 7, pmbl., ¶ 7; id. art. 21, ¶¶ 2, 3. 
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IV. RIGHTS OF AMENDMENT AND RECTIFICATION 
Under the Privacy Rule, an individual generally has the right to have a 
covered entity amend PHI or a record about the individual for as long as the 
PHI is maintained in the designated record set.108  There are several 
exceptions to this right.  For example, a covered entity is permitted to deny 
a request for amendment if the information is, indeed, accurate and 
complete,109 or if the covered entity that is being asked to amend the 
information did not create the information.110  Thus, the right is best framed 
as a right to have amended incorrect or incomplete PHI by the creator of the 
PHI.  Individuals must be told of this right through their covered entities’ 
notices of privacy practices (NOPP).111 
The GDPR has a rectification provision that is almost identical to the 
Privacy Rule’s amendment provision.  That is, the GDPR gives data subjects 
the right to obtain rectification of inaccurate personal data from the controller 
without undue delay and “the right to have incomplete personal data 
completed, including by means of providing a supplementary statement.”112  
The EU states in the Preamble to the GDPR that, “[e]very reasonable step 
should be taken to ensure that personal data which are inaccurate are rectified 
or deleted.”113  Like the NOPP requirement, the GDPR also requires data 
controllers, at the time when personal data are obtained and even when 
personal data are not obtained, to provide the data subject with information 
regarding his or her right to request rectification.114 
V. RIGHT TO ERASURE 
One area where the Privacy Rule and the GDPR are very different is 
with respect to the GDPR’s right to erasure, also called the right to be 
forgotten.115  This right gives data subjects the ability to obtain from the 
controller the erasure of personal data concerning him or her without undue 
delay when one of the following illustrative, but not exhaustive, grounds 
applies: 
(a) the personal data are no longer necessary in relation to the 
purposes for which they were collected or otherwise 
processed; . . . (c) the data subject objects to processing . . . and 
 
 108  Privacy of Individually Identifiable Health Information, 45 C.F.R. § 164.526(a)(1) 
(2016). 
 109  Id. § 164.526(a)(2)(iv). 
 110  Id. § 164.526(a)(2)(i). 
 111  Id. § 164.520(b)(1)(iv)(D). 
 112  EU GDPR, supra note 7, art. 16. 
 113  Id. pmbl., ¶ 39. 
 114  Id. art. 13, ¶ 2(b); id. art. 14, ¶ 2(c). 
 115  Id. art. 17. 
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there are no overriding legitimate grounds for the processing; . . . 
(d) the personal data have been unlawfully processed; 
(e) the personal data have to be erased for compliance with a legal 
obligation in Union or Member State law to which the controller 
is subject.116 
The GDPR further requires controllers to establish modalities, 
including electronic request modalities, that facilitate the exercise of the right 
to erasure of personal data.117 
The Privacy Rule not only does not contain a right to erasure, but it also 
does not modify federal and state medical record and other record retention 
requirements.  For example, the federal Medicare Conditions of Participation 
require Medicare-participating hospitals to maintain hospital medical 
records for five years.118  Many state medical practice acts require physicians 
licensed in those states to maintain their own medical records for a set period, 
such as seven years.119  In addition to federal and state medical record 
retention requirements, there exist other health compliance record retention 
requirements.  For example, the Privacy Rule requires covered entities to 
maintain documentation required by the Privacy Rule for six years from the 
date when the documentation was created or was last in effect, whichever is 
later, even if the patient or insured no longer has contact with the covered 
entity.120 
The GDPR does have exceptions to the right to erasure that address 
situations in which retention is: (1) necessary to comply with a legal 
obligation under Union or Member State law; (2) desirable for public health 
reasons; or (3) desirable for scientific archiving reasons.121  These three 
illustrative exceptions somewhat map on to the medical record and HIPAA 
documentation maintenance requirements discussed immediately above.  
Again, however, note the difference in approach.  That is, general federal 
and state health law and the Privacy Rule require the maintenance of medical 
records and HIPAA documentation for a certain period of time.  The GDPR 
requires erasure except when an exception applies. 
 
 
 
 116  Id. art. 17(1)(a), (c), (d) & (e).  
 117  Id. pmbl., ¶ 59.  
 118  Conditions of Participation for Hospitals, 42 C.F.R. § 482.24(b)(1) (2016). 
 119  See, e.g., 22 TEX. ADMIN. CODE § 165.1(b)(1) (2016). 
 120  Privacy of Individually Identifiable Information, 45 C.F.R. § 164.530(j)(2) (2016). 
 121  See EU GDPR, supra note 7, art. 17, ¶ 3, for a list of all the exceptions to the right to 
erasure. 
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CONCLUSIONS 
This Article has compared and contrasted the Privacy Rule and the 
GDPR in three contexts, including authorization and consent, amendment 
and rectification, and erasure.  There are many similarities between the 
concepts of authorization under the Privacy Rule and consent under the 
GDPR.  Obvious similarities include: (1) the expression of concern relating 
to clarity and separation of presentation of the authorization under the 
Privacy Rule and consent under the GDPR; (2) the prohibition of 
conditioning services on an authorization under the Privacy Rule and the 
assessment of such conditioning with respect to the voluntariness of consent 
under the GDPR; (3) the right of an individual to revoke an authorization 
under the Privacy Rule and to withdraw a consent under the GDPR; and (4) 
significant concerns relating to the use and disclosure of PHI for marketing 
under the Privacy Rule and the processing of personal data for direct 
marketing under the GDPR. 
The terminology, organization, and presentation of these concerns, 
prohibitions, and rights in the Privacy Rule and the GDPR certainly are 
different.  The most notable difference—and the best illustration of such a 
difference—is the Privacy Rule’s heavy-handed regulation of the content of 
the authorization, including the six core elements and three required 
statements that must be in every authorization. 
It would be tempting to say that the Privacy Rule is, across the board, 
more detailed and directive than the GDPR.  For example, the Privacy Rule 
contains a strong prohibition against combining authorizations with other 
documents, whereas the GDPR allows consent to be presented in the context 
of a written declaration concerning other matters so long as the request for 
consent is presented in a manner that is clearly distinguishable from such 
other matters.  However, the GDPR does contain greater particularity and 
regulatory rigidity in some contexts, including its requirement relating to the 
ease of consent withdrawal. 
With respect to the rights of amendment and rectification of inaccurate 
or incomplete data, the Privacy Rule and the GDPR are very similar.  The 
regulatory language––amendment versus rectification––is the biggest 
difference.  A significant difference, however, lies in the GDPR’s right to 
erasure and the lack of comparable language in the Privacy Rule.  In general, 
federal and state health law, including the Privacy Rule, require retention of 
medical records, billing records, compliance records, and other records for 
at least five years, if not longer.  There are important clinical reasons for 
these record retention requirements.  Clinicians need to know, for example, 
whether a patient is allergic to a drug or has had an adverse drug reaction in 
the past, and older medical records are critical in terms of providing this 
information and preventing drug and other injuries. 
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Health insurers, too, need to maintain billing and payment records for 
purposes of determining whether patients have satisfied their annual 
deductibles, have met their annual out-of-pocket maximums and, if President 
Trump repeals the Affordable Care Act, whether insureds or applicants for 
insurance have preexisting health conditions that could make them ineligible 
for insurance coverage of a future illness. 
Health oversight agencies, including the Centers for Medicare and 
Medicaid Services, the Office for Civil Rights, and the Drug Enforcement 
Agency, also need billing and other administrative records to identify health 
care fraud and abuse, to detect privacy violations, and to become aware of 
problematic prescription patterns. 
In summary, the obligation to maintain and the ability to produce 
health-related records upon request is critical to the smooth functioning of 
the health care delivery system as well as the health care financing system, 
helping to explain some of the key differences between the GDPR and the 
Privacy Rule, especially with respect to erasure. 
 
